|
|
Humanization of a mouse anti-OX40 monoclonal antibody to treat cancer
|
5R43CA159797-02
|
$106,505
|
$53,253
|
TRIGLIA, DENNIS
|
AGONOX, INC.
|
|
|
Nemours Community Clinical Oncology Program
|
3U10CA176879-01S1
|
$89,460
|
$895
|
SANDLER, ERIC
|
ALFRED I. DU PONT HOSP FOR CHILDREN
|
|
|
Advances in Melanoma: From Biology to Therapy
|
1R13CA189528-01
|
$4,000
|
$4,000
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
|
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma
|
3R41CA174008-01A1S1
|
$160,721
|
$160,721
|
JONES, BARRY
|
ARISAPH PHARMACEUTICALS, INC.
|
|
|
Bay Area Tumor Institute CCOP
|
3U10CA045461-24S1
|
$81,028
|
$810
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S1
|
$75,000
|
$750
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S3
|
$48,834
|
$488
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-08S4
|
$149,801
|
$1,498
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-08
|
$2,746,741
|
$27,467
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
TARGETING INOS TO INHIBIT MYELOID-DERIVED SUPPRESSOR CELLS (MDSC) IN MELANOMA
|
7K08CA154963-04
|
$134,865
|
$134,865
|
SIKORA, ANDREW
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Cancer and Stroma-Targeted Immunotherapy with a Gentically Modified DC Vaccine
|
5R01CA148748-04
|
$315,831
|
$315,831
|
SONG, XIAO-TONG
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
CpG-ODN Coated Hollow Gold Nanoshells for Photothermal Therapy
|
5R01CA172836-02
|
$332,608
|
$166,304
|
FOSTER, AARON
|
BELLICUM PHARMACEUTICALS, INC.
|
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-29S1
|
$86,403
|
$864
|
NICHOLS, CRAIG
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)
|
5R01CA170158-03
|
$350,219
|
$87,555
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
The Role of Post Traumatic Stress and Substance P in Melanoma Brain Metastasis
|
5R03CA172923-02
|
$84,390
|
$84,390
|
WONG, ERIC
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S5
|
$110,177
|
$1,102
|
KACHNIC, LISA
|
BOSTON MEDICAL CENTER
|
|
|
The role of pheomelanin in cutaneous melanoma
|
5R01CA137098-07
|
$329,488
|
$329,488
|
CUI, RUTAO
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
BMP7 in melanoma niche morphogenesis and homeostasis
|
5R01CA138649-05
|
$319,603
|
$319,603
|
HSU, MEI-YU
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Elucidating the Function of the NF1 Tumor Suppressor and its Effector Pathways in
|
5R01CA111754-10
|
$276,167
|
$138,084
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Functional Analysis of Galectin-1 Ligands in Melanoma Progression
|
5R01CA173610-02
|
$349,346
|
$349,346
|
DIMITROFF, CHARLES
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Multifunctional nanoparticles for targeting aberrant tumorigenic pathways
|
5R01CA135242-05
|
$348,498
|
$115,004
|
SENGUPTA, SHILADITYA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Stem Cell-Engineered Tumor Immunity in Man
|
5P01CA132681-05
|
$2,795,193
|
$2,795,193
|
BALTIMORE, DAVID
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
|
Strategies for Distinguishing Success in Immunotherapy Treatments (PQ20)
|
5R01CA170689-03
|
$607,965
|
$607,965
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
|
Nanosystems Biology Cancer Center 2
|
5U54CA151819-05
|
$2,357,460
|
$400,768
|
HEATH, JAMES
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
|
PHIP as a Biomarker of Triple-Negative Melanoma
|
1R01CA175768-01A1
|
$424,835
|
$424,835
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
|
Validation of Genomic Targets in Melanoma
|
5R01CA114337-10
|
$305,300
|
$305,300
|
KASHANI-SABET, MOHAMMED
|
CALIFORNIA PACIFIC MED CTR RES INSTITUTE
|
|
|
Cruciferous Dithiolethiones for Chronic Heart Failure: Signaling Mechanisms
|
1R15CA192936-01A1
|
$469,400
|
$469,400
|
LI, YUNBO
|
CAMPBELL UNIVERSITY
|
|
|
Targeting the developmental pathways Notch and ERBB for melanoma therapy
|
1R01CA177652-01A1
|
$363,241
|
$363,241
|
BEDOGNI, BARBARA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Bone Marrow MSCs/Pericytes: Gatekeepers Controlling Skeletal Metastasis.
|
5R01CA163562-03
|
$316,002
|
$158,001
|
CAPLAN, ARNOLD
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S1
|
$74,051
|
$1,481
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S2
|
$29,166
|
$583
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S3
|
$145,188
|
$2,904
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-24
|
$4,748,649
|
$94,973
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
1U10CA180853-01
|
$1,188,450
|
$29,711
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Immunology of human malignant melanoma initiating cells
|
5R01CA158467-03
|
$353,203
|
$353,203
|
FRANK, MARKUS
|
CHILDREN'S HOSPITAL CORPORATION
|
|
|
Cancer biology in the zebrafish
|
5R01CA103846-12
|
$358,651
|
$358,651
|
ZON, LEONARD
|
CHILDREN'S HOSPITAL CORPORATION
|
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
3U10CA045418-27S1
|
$237,321
|
$2,373
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
|
Integrative Cancer Genomics: Drivers, Pathways and Drugs
|
5R01CA164729-03
|
$101,640
|
$15,246
|
PE'ER, DANA
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
|
Columbia University Medical Center Minority-Based Community Clinical Oncology Pro
|
3U10CA167791-02S1
|
$73,416
|
$734
|
KELLY, KARA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Columbus Community Clinical Oncology Program (Columbus CCOP)
|
3U10CA035261-30S1
|
$135,525
|
$1,355
|
KUEBLER, PHILIP
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
|
Cancer Center Support Grant
|
3P30CA006516-49S1
|
$118,825
|
$4,753
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
|
Cancer Center Support Grant
|
3P30CA006516-49S2
|
$75,000
|
$3,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
|
Cancer Center Support Grant
|
3P30CA006516-49S3
|
$12,500
|
$500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
|
Cancer Center Support Grant
|
5P30CA006516-49
|
$10,827,666
|
$433,107
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
|
Targeting MFG-E8 as Melanoma Immunotherapy
|
5R01CA143083-05
|
$306,522
|
$306,522
|
DRANOFF, GLENN
|
DANA-FARBER CANCER INST
|
|
|
Developing Selective EphA2 Inhibitors for the treatment of Cancer
|
5R01CA173469-02
|
$508,812
|
$203,525
|
GRAY, NATHANAEL
|
DANA-FARBER CANCER INST
|
|
|
Comparative Assessment of Screening Strategies for Melanoma
|
1R21CA182241-01A1
|
$188,138
|
$188,138
|
LEE, SANDRA
|
DANA-FARBER CANCER INST
|
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
1R01CA185151-01
|
$603,086
|
$603,086
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
|
Analysis of cap-dependent translational repression by microRNAs in oncogensis
|
5R01CA140986-04
|
$317,009
|
$317,009
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
|
Metabolic Vulnerabilities in Melanoma Tumors
|
1R01CA181217-01A1
|
$348,404
|
$348,404
|
PUIGSERVER, PERE
|
DANA-FARBER CANCER INST
|
|
Total relevant funding to Melanoma for this search: $126,208,058
|
